We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Breakthrough Diagnostic Technology Enables Quantitative Five-Minute Tests

By LabMedica International staff writers
Posted on 09 Nov 2022

Fast and accurate diagnostic results have become familiar. More...

But many medical decisions rely on a quantitative diagnostic result. The doctor needs a number, not just a positive or negative. Now, a breakthrough diagnostic technology enables quantitative five-minute tests that deliver easy, immediate and accurate results to expedite medical treatment.

ProciseDx Inc. (San Diego, CA, USA) has received FDA clearance of its ProciseDx instrument and C reactive Protein (CRP) test. Procise CRP gives quantitative determination of CRP levels in patient serum in less than five minutes. The company expects FDA clearances of additional tests in 2023. ProciseDx has a menu of five-minute gastroenterology and Therapeutic Drug Monitoring (TDM) tests available in Europe.

ProciseDx has obtained CE Marks and launched four gastroenterology (GI) tests in Europe. Already 30 ProciseDx instruments are installed and supporting patient care, with a further 50 sites working towards implementation. For the US market, ProciseDx has submitted De Novo applications to the FDA for two TDM tests. Procise IFX measures infliximab (Remicade and biosimilars) and Procise ADL measures adalimumab (Humira and biosimilars). ProciseDx expects to commercialize its GI and TDM menu in the US in 2023, launching with Procise IFX, Procise ADL and Procise CRP.

"Accurate quantitative diagnostic results have typically required big lab instruments and taken several hours or days," said Larry Mimms, President & Chief Scientific Officer. "The ProciseDx platform can change that, with a simple workflow producing a reliable quantitative measurement in five minutes or less."

"Remicade and Humira are hugely important drugs for patients with IBD (Inflammatory Bowel Disease) and ProciseDx monitoring of these drugs is improving care in Europe," said Peter Westlake, ProciseDx CEO. "ProciseDx technology is a real step forward, because it can deliver reliable quantitative results from a drop of blood in five minutes or less. We're preparing to bring these additional ProciseDx five-minute tests to doctors and patients in the US."

Related Links:
ProciseDx Inc.


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
New
Specimen Radiography System
TrueView 200 Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.